Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

ly in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


Contacts:
GendeLLindheim BioCom Partners
Investors                          Media
---------                          -----
info@peregrineinc.com              Barbara Lindheim
(800) 987-8256                     (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... GPRO ) announced today that the Company will present ... Tuesday, November 18,2008 at approximately 3:10 p.m. Eastern Time. ... be accessed through a link on the investors,section of ... available for 30 days following the event., About ...
... November 14, 2008 at 9:00 a.m. Eastern ... ... Inc. (Nasdaq: ALSE ) today reports operational and,financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the ...
... PharmAthene, Inc.,(NYSE Alternext US: PIP), a biodefense company ... reported,financial and operational results for the third quarter ... the third quarter of 2008, PharmAthene recognized revenues ... same period of 2007. For the nine,months ended ...
Cached Biology Technology:Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7
(Date:7/10/2014)... cutting-edge, innovative research on Alzheimer,s disease and the ... announced the recipients of new research grant awards, ... the District of Columbia, and five foreign countries. ... latest grants, BrightFocus has now provided more than ... The research projects funded this year reflect a ...
(Date:7/10/2014)... the strong currents in the Straits of Mackinac reverse ... pipeline beneath the channel would quickly contaminate shorelines miles ... a new University of Michigan study commissioned by the ... the study and accompanying animations, oil from a hypothetical ... 12 hours and Bois Blanc Island after two days. ...
(Date:7/10/2014)... NY (July 10, 2014) Columbia University Medical Center ... gene therapies for patients with retinitis pigmentosa (RP), a ... of its kind, takes advantage of induced pluripotent stem ... cells, which are then used as a patient-specific model ... approach, researchers led by Stephen H. Tsang, MD, PhD, ...
Breaking Biology News(10 mins):BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
... Geologists have a new tool to study how earthquakes change ... into how earthquake faults behave. In this week,s issue ... from the United States, Mexico and China reports the most ... from the magnitude 7.2 event that struck near Mexicali, Mexico, ...
... Researchers at Northwestern University have developed a new ... providing an alternative that is more flexible and ... describing the results, "Low-Pressure Foaming: A Novel Method ... Engineering," was featured in the February issue of ...
... hosts a panel discussion and open public forum about ... for Biosecurity (NSABB), which advises the U.S. Department of ... journals that they redact key information from unpublished manuscripts ... both good and bad purposes. The research in ...
Cached Biology News:3-D laser map shows earthquake zone before and after 23-D laser map shows earthquake zone before and after 3Researchers develop new method for creating tissue engineering scaffolds 2Georgetown hosts forum to discuss government request of journals to redact scientific data 2
... now entered the next frontier of cell-based ... with Cellomics, Inc. The drug discovery process ... Coulter‘s automated solutions systems and Cellomics‘ HCS ... the sub-cellular level. The integration of these ...
... Todays research and biologic production demands on ... to confirming viable cell populations. Therefore, both ... must be determined accurately and precisely. The ... automatic and cost effective means to perform ...
... SureLINK Bioconjugation Kit provides a powerful yet ... and nuceleic acids. The kit provides the ... reagents for quantifying conjugation efficiencies. It enables ... biotin and other tags with a variety ...
... Lumat tube luminometer provides the sensitivity and ... luminometer. Advanced digital photon counting with selected ... of spectral demands. Equipped with up to ... suited for reporter gene assays as well ...
Biology Products: